Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer

Affiliations

• 1 Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.
• 2 Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
• 3 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatchewan, Canada.
• 4 Department of Experimental Therapeutics, BC Cancer, Vancouver, British Columbia, Canada.
• 5 Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
• 6 Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
• 7 Division of Oncology, Cancer Cluster, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada.
• 8 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
• 9 Department of Oncology, University of Alberta, Edmonton, Alberta, Canada; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
• 10 Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, Alberta, Canada.
• 11 Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada; Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
• 12 Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: chenghanlee@gmail.com.